With Bristol-Myers Squibb Co.’s checkpoint inhibitor Opdivo (nivolumab) having a US FDA PDUFA date of Sept. 24, 2017, for use as a second-line therapy for hepatocellular carcinoma (HCC), and Eisai Co. Ltd.'s oral multiple receptor tyrosine kinase inhibitor, lenvatinib, submitted for US and European approval as first-line HCC therapy, announced on July 25, changes are afoot in this therapeutic area. (Also see "Lenvatinib HCC Results Give Sorafenib Cause To REFLECT?" - Scrip, 6 June, 2017.)
Liver Cancer: What's Close To The Market
The treatment of liver cancer will have a makeover in coming months, with several products including Bristol’s Opdivo nearing the market for a disease that is often diagnosed late and where previously there have been few meaningful advances in therapy for many years. Two recently published reports from Datamonitor Healthcare have reviewed the disease and the R&D pipeline for the condition.
More from Anticancer
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
More from Therapy Areas
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.